Adagio adopts new name, adds Covid cocktail candidate in ‘new day’ bid after initial drug development woes
Adagio is now Invivyd.
More than just a brand name change though, the biotech is adding a new Covid-19 drug candidate and looking for a refreshed start after a tumultuous stretch in Covid-19 drug development.
Along with the new Invivyd name, it announced on Monday a new antibody cocktail candidate for Covid prevention and treatment with studies set to begin in Q1 2023. The new NVD200 combines two monoclonal antibodies aimed at Omicron variants, and adds to the company’s efforts on its late-stage Covid candidate adintrevimab which was coasting along on a raft of positive data before Omicron emerged.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,600+ biopharma pros reading Endpoints daily — and it's free.